351 related articles for article (PubMed ID: 23041329)
1. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
[TBL] [Abstract][Full Text] [Related]
2. Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device.
Heberle CR; Omidvari AH; Ali A; Kroep S; Kong CY; Inadomi JM; Rubenstein JH; Tramontano AC; Dowling EC; Hazelton WD; Luebeck EG; Lansdorp-Vogelaar I; Hur C
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1397-1404.e7. PubMed ID: 28238953
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
Gerson LB; Groeneveld PW; Triadafilopoulos G
Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
[TBL] [Abstract][Full Text] [Related]
4. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis.
Gupta N; Bansal A; Wani SB; Gaddam S; Rastogi A; Sharma P
Gastrointest Endosc; 2011 Sep; 74(3):610-624.e2. PubMed ID: 21741639
[TBL] [Abstract][Full Text] [Related]
5. Economic value of narrow-band imaging versus white light endoscopy for the diagnosis and surveillance of Barrett's esophagus: Cost-consequence model.
Furneri G; Klausnitzer R; Haycock L; Ihara Z
PLoS One; 2019; 14(3):e0212916. PubMed ID: 30865673
[TBL] [Abstract][Full Text] [Related]
6. The cost effectiveness of radiofrequency ablation for Barrett's esophagus.
Hur C; Choi SE; Rubenstein JH; Kong CY; Nishioka NS; Provenzale DT; Inadomi JM
Gastroenterology; 2012 Sep; 143(3):567-575. PubMed ID: 22626608
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of screening a population with chronic gastroesophageal reflux.
Nietert PJ; Silverstein MD; Mokhashi MS; Kim CY; Glenn TF; Marsi VA; Hawes RH; Wallace MB
Gastrointest Endosc; 2003 Mar; 57(3):311-8. PubMed ID: 12612508
[TBL] [Abstract][Full Text] [Related]
8. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy.
Rubenstein JH; Inadomi JM; Brill JV; Eisen GM
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):312-8. PubMed ID: 17368230
[TBL] [Abstract][Full Text] [Related]
9. Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus.
Inadomi JM
Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):51-63. PubMed ID: 25743456
[TBL] [Abstract][Full Text] [Related]
10. Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.
Pilonis ND; Killcoyne S; Tan WK; O'Donovan M; Malhotra S; Tripathi M; Miremadi A; Debiram-Beecham I; Evans T; Phillips R; Morris DL; Vickery C; Harrison J; di Pietro M; Ortiz-Fernandez-Sordo J; Haidry R; Kerridge A; Sasieni PD; Fitzgerald RC
Lancet Oncol; 2022 Feb; 23(2):270-278. PubMed ID: 35030332
[TBL] [Abstract][Full Text] [Related]
11. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
12. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
13. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus.
Gerson L; Lin OS
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):319-25. PubMed ID: 17368231
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
15. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
Fitzgerald RC; di Pietro M; O'Donovan M; Maroni R; Muldrew B; Debiram-Beecham I; Gehrung M; Offman J; Tripathi M; Smith SG; Aigret B; Walter FM; Rubin G; ; Sasieni P
Lancet; 2020 Aug; 396(10247):333-344. PubMed ID: 32738955
[TBL] [Abstract][Full Text] [Related]
16. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
[TBL] [Abstract][Full Text] [Related]
17. Wide Area Transepithelial Sampling with Computer-Assisted Analysis (WATS
Singer ME; Smith MS
Dig Dis Sci; 2021 May; 66(5):1572-1579. PubMed ID: 32578042
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.
Ross-Innes CS; Chettouh H; Achilleos A; Galeano-Dalmau N; Debiram-Beecham I; MacRae S; Fessas P; Walker E; Varghese S; Evan T; Lao-Sirieix PS; O'Donovan M; Malhotra S; Novelli M; Disep B; Kaye PV; Lovat LB; Haidry R; Griffin M; Ragunath K; Bhandari P; Haycock A; Morris D; Attwood S; Dhar A; Rees C; Rutter MD; Ostler R; Aigret B; Sasieni PD; Fitzgerald RC;
Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):23-31. PubMed ID: 28404010
[TBL] [Abstract][Full Text] [Related]
19. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
Provenzale D; Schmitt C; Wong JB
Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
[TBL] [Abstract][Full Text] [Related]
20. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
